Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants must be 21 to 75 years of age inclusive, at the time of signing the informed consent form (ICF).~* Evidence of steatosis by Fibroscan and magnetic resonance imaging based proton density fat fraction (MRI-PDFF)~* NASH or NAFLD at high risk for NASH as reflected by AT LEAST ONE of the following:~* Diagnosis of NASH with fibrosis (stages F1, F2 or F3), without cirrhosis, by percutaneous liver biopsy within 24 months prior to screening~* Central obesity WITH type 2 diabetes mellitus (T2DM)~* Central obesity WITH either increased alanine transaminase (ALT) and/or Fibroscan vibration-controlled transient elastography (VCTE) score ≥7 KPa.~* Part 2 only: Biopsy-proven NASH in a liver biopsy obtained within 24 weeks of baseline with fibrosis stage F2 or F3 and NAS ≥4, with a score of at least 1 in each of steatosis, ballooning degeneration, and lobular inflammation. A small number of high risk F1 allowed.~Key Exclusion Criteria:~* Clinically significant disorder or a history of any illness that, in the opinion of the Investigator, might confound the results of the study, or pose additional risk to the participant by participation in the study.~* History of type 1 diabetes.~* Weight loss of more than 5% within 3 months prior to Day -1 or more than 10% within 6 months prior to Day -1 or planning to try to lose weight during conduct of study.~* History of a liver disorder other than NASH or clinical suspicion of a liver disorder other than NASH~* History of cirrhosis or evidence of cirrhosis

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part 1: Pegozafermin 3 milligrams (mg) weekly (QW) (Type: EXPERIMENTAL): Participants were administered 3 mg of pegozafermin QW, via subcutaneous (SC) injection, starting on Day 1 through Day 85.
- Part 1: Pegozafermin 9 mg QW (Type: EXPERIMENTAL): Participants were administered 9 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.
- Part 1: Pegozafermin 18 mg QW (Type: EXPERIMENTAL): Participants were administered 18 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.
- Part 1: Pegozafermin 27 mg QW (Type: EXPERIMENTAL): Participants were administered 27 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 85.
- Part 1: Pegozafermin 18 mg Every 2 Weeks (Q2W) (Type: EXPERIMENTAL): Participants were administered 18 mg of pegozafermin Q2W, via SC injection, starting on Day 1 through Day 85.
- Part 1: Pegozafermin 36 mg Q2W (Type: EXPERIMENTAL): Participants were administered 36 mg of pegozafermin Q2W, via SC injection, starting on Day 1 through Day 85.
- Part 1: Placebo QW or Q2W (Type: PLACEBO_COMPARATOR): Participants were administered placebo matching to pegozafermin QW or Q2W, via SC injection, starting on Day 1 through Day 85.
- Part 2: Pegozafermin 27 mg QW (Type: EXPERIMENTAL): Participants were administered 27 mg of pegozafermin QW, via SC injection, starting on Day 1 through Day 134.

Based on this trial design, predict the completion outcome and termination type (if applicable).